High Seroprevalence of SARS-CoV-2 in White-Tailed Deer (Odocoileus virginianus) at One of Three Captive Cervid Facilities in Texas
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
As SARS-CoV-2 vaccine coverage of the human population increases and variants of concern continue to emerge, identification of the epidemiologic importance of animal virus reservoirs is critical. We found that nearly all (94.4%) of the captive white-tailed deer at a cervid facility in central Texas had neutralizing antibodies for SARS-CoV-2.
Article activity feed
-
-
SciScore for 10.1101/2022.01.05.475172: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: TX, with approximately 207 captive white-tailed deer (57 bucks, 150 does) used for breeding and research purposes; twenty-one of these does were previously enrolled in experimental anthrax vaccine work that involved being handled individually for <1 minute for blood collection at approximately monthly time points from November 2020 – July 2021, with each hands-on interaction lasting less than one minute.
IACUC: All samples were collected in accordance with the relevant guidelines and regulations approved by the TAMU’s Institutional Animal Care and Use Committee and Clinical Research Review Committee (2018-0460 CA)Sex as a biological variable not detected. Randomization not … SciScore for 10.1101/2022.01.05.475172: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: TX, with approximately 207 captive white-tailed deer (57 bucks, 150 does) used for breeding and research purposes; twenty-one of these does were previously enrolled in experimental anthrax vaccine work that involved being handled individually for <1 minute for blood collection at approximately monthly time points from November 2020 – July 2021, with each hands-on interaction lasting less than one minute.
IACUC: All samples were collected in accordance with the relevant guidelines and regulations approved by the TAMU’s Institutional Animal Care and Use Committee and Clinical Research Review Committee (2018-0460 CA)Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Serum samples were tested by PRNT to quantify antibodies able to neutralize the formation of SARS-CoV-2 plaques on Vero cell cultures following standard protocols (21) in a BSL3 laboratory. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
